



Market Announcement

24 October 2024

Nyrada Inc. (ASX: NYR) – Trading Halt

Description

The securities of Nyrada Inc. ('NYR') will be placed in trading halt at the request of NYR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 28 October 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

For personal use only



24 October 2024

Sydney, Australia

ASX Limited
Listings Compliance, Sydney
20 Bridge Street
Sydney NSW 2000

Attention: Ms Yulia Gurdina (Senior Adviser, Listings Compliance (Sydney))

By Email Only: tradinghaltssydney@asx.com.au

Dear Ms Gurdina,

TRADING HALT REQUEST

Nyrada Inc [ASX:NYR] (**Company or Nyrada**) hereby requests a trading halt in relation to the Company's Chess Depository Interests (CDIs) quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company to the market regarding a proposed capital raising (**the Purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is necessary to assist Nyrada in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated Purpose above.
- Nyrada requests that the trading halt remain in place until the earlier of commencement of normal trading on Monday, 28 October 2024, or when the announcement regarding the stated Purpose is released to the market.
- Nyrada is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

For and on behalf of the Board of Nyrada Inc.

Yours faithfully,

David Franks
Company Secretary

-ENDS-



About Nyrada Inc

Nyrada Inc. is a biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. James Bonnar, Chief Executive Officer on behalf of the Board.

Investor:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: david.franks@atomicgroup.com.au

Media Enquiries:

Catherine Strong

Sodali & Co

T: 02 8234 0111

E: catherine.strong@sodali.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.